Frequency Therapeutics 将来の成長

Future 基準チェック /06

Frequency Therapeutics の収益は、年間 4.7% 減少すると予測されています。EPS は、年間増加すると予測されています10.4%。

主要情報

-4.7%

収益成長率

10.4%

EPS成長率

Biotechs 収益成長	28.3%
収益成長率	n/a
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	26 Sep 2023

今後の成長に関する最新情報

Recent updates

Is Frequency Therapeutics (NASDAQ:FREQ) Weighed On By Its Debt Load?

Jan 01

Frequency Therapeutics (NASDAQ:FREQ) Has Debt But No Earnings; Should You Worry?

Jan 19

Frequency Therapeutics, Inc. (NASDAQ:FREQ) Analysts Are Reducing Their Forecasts For This Year

Aug 18

Health Check: How Prudently Does Frequency Therapeutics (NASDAQ:FREQ) Use Debt?

Jul 31

Frequency Therapeutics (FREQ) Investor Presentation - Slideshow

Jun 18

Frequency Therapeutics: A Look At What's Next After A Disappointing Data Readout

Apr 21

Frequency Therapeutics, Inc. (NASDAQ:FREQ) Analysts Are More Bearish Than They Used To Be

Apr 04

We're Not Worried About Frequency Therapeutics' (NASDAQ:FREQ) Cash Burn

Mar 15

If You Had Bought Frequency Therapeutics (NASDAQ:FREQ) Shares A Year Ago You'd Have Earned 55% Returns

Jan 22

Have Insiders Sold Frequency Therapeutics, Inc. (NASDAQ:FREQ) Shares Recently?

Dec 27

Frequency Therapeutics to host investor event in early January next year

Dec 18

How Much Are Frequency Therapeutics, Inc. (NASDAQ:FREQ) Insiders Taking Off The Table?

Dec 10

Frequency Therapeutics, Inc. (NASDAQ:FREQ) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Nov 19

Frequency Therapeutics EPS beats by $0.16, beats on revenue

Nov 16

Frequency Therapeutics Is An Interesting Speculative Play Ahead Of Phase 2 Results

Nov 09

業績と収益の成長予測

NasdaqCM:FREQ - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2025	N/A	-57	N/A	N/A	1
12/31/2024	N/A	-44	N/A	N/A	2
12/31/2023	N/A	-50	N/A	N/A	2
9/30/2023	N/A	-59	-43	-43	N/A
6/30/2023	N/A	-67	-50	-50	N/A
3/31/2023	N/A	-78	-55	-55	N/A
12/31/2022	N/A	-82	-58	-58	N/A
9/30/2022	N/A	-86	-61	-61	N/A
6/30/2022	N/A	-91	-64	-64	N/A
3/31/2022	9	-88	-70	-68	N/A
12/31/2021	14	-85	-79	-76	N/A
9/30/2021	24	-73	-80	-73	N/A
6/30/2021	35	-54	-77	-69	N/A
3/31/2021	34	-42	-68	-61	N/A
12/31/2020	37	-27	-52	-45	N/A
9/30/2020	32	-22	-63	-60	N/A
6/30/2020	45	-18	23	25	N/A
3/31/2020	36	-19	30	31	N/A
12/31/2019	29	-20	33	34	N/A
9/30/2019	24	-20	58	59	N/A
6/30/2019	N/A	-23	-20	-19	N/A
3/31/2019	N/A	-21	-20	-19	N/A
12/31/2018	N/A	-19	-17	-17	N/A

アナリストによる今後の成長予測

収入対貯蓄率: FREQ今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: FREQ今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: FREQ今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: FREQの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。

高い収益成長: FREQ来年は収益がないと予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: FREQの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Frequency Therapeutics 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Price target decreased to US$6.67

Consensus forecasts updated

Price target decreased to US$12.00

Price target increased to US$14.33

Price target decreased to US$12.75

Consensus revenue estimates fall to US$36.2m

Recent updates

Korro Bio, Inc. completed the acquisition of Frequency Therapeutics, Inc. (NasdaqGS:FREQ) from a group of shareholders.

Korro Bio, Inc. completed the acquisition of Frequency Therapeutics, Inc. (NasdaqGS:FREQ) from a group of shareholders.

New major risk - Market cap size

Insufficient new directors

New major risk - Financial position

Frequency Therapeutics, Inc. Announces the Resignation of Christopher Loose as Chief Scientific Officer

New major risk - Share price stability

Korro Bio, Inc. entered into a definitive merger agreement to acquire Frequency Therapeutics, Inc. (NasdaqGS:FREQ) from a group of shareholders in a reverse merger transaction.

Frequency Therapeutics, Inc. Announces Topline Results for its Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss

Is Frequency Therapeutics (NASDAQ:FREQ) Weighed On By Its Debt Load?

Frequency Therapeutics, Inc. Announces First Patient Dosed in Phase 1b Study of FX-345, the Company’s Second Therapeutic Candidate for Sensorineural Hearing Loss

Price target decreased to US$6.67

Frequency Therapeutics, Inc. Completes Enrollment of Phase 2B Study of FX-322 for the Treatment of Sensorineural Hearing Loss

Frequency Therapeutics, Inc.(NasdaqGS:FREQ) dropped from Russell 2500 Index

Consensus forecasts updated

First quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Frequency Therapeutics, Inc., Annual General Meeting, Jun 21, 2022

Price target decreased to US$12.00

Insufficient new directors

Frequency Therapeutics, Inc. Announces Peter P. Pfreundschuh Stepping Down as Chief Financial Officer

Price target increased to US$14.33

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Frequency Therapeutics (NASDAQ:FREQ) Has Debt But No Earnings; Should You Worry?

Insufficient new directors

Frequency Therapeutics, Inc. Shares Results from FX-322-113 Severe Sensorineural Hearing Loss Study Showing Speech Perception Improvements in Noise

Frequency Therapeutics, Inc. Announces New FX-322 Results Showing that Additional Study Participants Gain Hearing Improvements at Later Time Points

Price target decreased to US$12.75

Consensus revenue estimates fall to US$36.2m

Frequency Therapeutics, Inc. (NASDAQ:FREQ) Analysts Are Reducing Their Forecasts For This Year

Second quarter 2021 earnings released: US$0.52 loss per share (vs US$0.19 loss in 2Q 2020)

Health Check: How Prudently Does Frequency Therapeutics (NASDAQ:FREQ) Use Debt?

Lieff Cabraser Heimann & Bernstein, LLP Announces That Class Action Litigation Has Been Filed Against Frequency Therapeutics, Inc

Frequency Therapeutics, Inc.(NasdaqGS:FREQ) dropped from Russell 2500 Growth Index

Co-Founder exercised options to buy US$1.1m worth of stock.

Frequency Therapeutics (FREQ) Investor Presentation - Slideshow

Rosen Law Firm Encourages Frequency Therapeutics, Inc. Investors with Losses Exceeding $100,000 to Secure Counsel Before Important Deadline

Price target decreased to US$14.25

Consensus forecasts updated

Forecast to breakeven in 2025

Insider recently bought US$89k worth of stock

Consensus forecasts updated

First quarter 2021 earnings released: US$0.60 loss per share (vs US$0.16 loss in 1Q 2020)

Frequency Therapeutics: A Look At What's Next After A Disappointing Data Readout

Frequency Therapeutics, Inc. (NASDAQ:FREQ) Analysts Are More Bearish Than They Used To Be

Full year 2020 earnings released: US$0.82 loss per share (vs US$2.29 loss in FY 2019)

Independent Director exercised options to buy US$316k worth of stock.

We're Not Worried About Frequency Therapeutics' (NASDAQ:FREQ) Cash Burn

Co-­Founder exercised options and sold US$469k worth of stock

Frequency Therapeutics, Inc. Announces Publication of Phase 1/2 Data Showing Hearing Improvements in Acquired Sensorineural Hearing Loss Patients Receiving FX-322

New 90-day high: US$54.87

Frequency Therapeutics, Inc. Appoints Kevin Franck as Senior Vice President of Strategic Marketing and New Product Planning

Co-­Founder exercised options and sold US$385k worth of stock

New 90-day high: US$40.50

If You Had Bought Frequency Therapeutics (NASDAQ:FREQ) Shares A Year Ago You'd Have Earned 55% Returns

Frequency Therapeutics Appoints Quentin McCubbin, Ph.D., as Chief Manufacturing Officer

Co-­Founder exercised options and sold US$594k worth of stock

Have Insiders Sold Frequency Therapeutics, Inc. (NASDAQ:FREQ) Shares Recently?

Independent Director recently sold US$1.7m worth of stock

Frequency Therapeutics, Inc. Enters into an Agreement for Termination of Lease and Voluntary Surrender of Premises

Frequency Therapeutics to host investor event in early January next year

Price target raised to US$36.33

Co-­Founder exercised options and sold US$437k worth of stock

How Much Are Frequency Therapeutics, Inc. (NASDAQ:FREQ) Insiders Taking Off The Table?

New 90-day high: US$28.86

Frequency Therapeutics Appoints Peter Pfreundschuh as Chief Financial Officer

Frequency Therapeutics, Inc. (NASDAQ:FREQ) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Third quarter 2020 earnings released: US$0.16 loss per share

Revenue beats expectations, earnings disappoint

Frequency Therapeutics EPS beats by $0.16, beats on revenue

Co-Founder exercised options and sold US$469k worth of stock

Co-Founder exercised options and sold US$385k worth of stock

Co-Founder exercised options and sold US$594k worth of stock

Co-Founder exercised options and sold US$437k worth of stock

Co-Founder & Chief Scientific Officer notifies of intention to sell stock